@article{3137869,
    title = "Non-gastric extra-nodal marginal zone lymphomas-a single centre
experience on 76 patients",
    author = "Kalpadakis, Christina and Pangalis, Gerassimos A. and Vassilakopoulos, and Theodoros P. and Kyrtsonis, Maria-Christina and Siakantaris, Marina P. and and Kontopidou, Flora N. and Korkolopoulou, Penelope and Bobotsis, and Panagia and Sahanas, Sotirios and Tzenou, Tatiana and Anagnostou, and Dimitra and Dimitriadou, Evangelia and Yiakoumis, Xanthi and Patsouris, and Evangelos and Roussou, Panagiota and Panayiotidis, Panayiotis and and Papadaki, Eleni and Angelopoulou, Maria K.",
    journal = "Leukemia & Lymphoma",
    year = "2008",
    volume = "49",
    number = "12",
    pages = "2308-2315",
    publisher = "TAYLOR & FRANCIS LTD LONDON",
    issn = "1042-8194, 1029-2403",
    doi = "10.1080/10428190802510331",
    keywords = "MALT; lymphoma; extranodal marginal zone lymphoma",
    abstract = "In the present study, we assessed the clinical and pathological data of
76 patients with the diagnosis of non-gastric extranodal marginal zone
B-cell lymphoma. The most commonly affected sites were salivary glands,
skin, ocular adnexa, lung, intestine and Waldeyer’s ring. Ann Arbor
stage I disease was present in 39 patients (51%), stage II in 10 (13%)
and stage IV in 27 (36%). In 17 cases (21%), the lymphoma presented at
multiple mucosal sites. Lymph node and bone marrow involvement were
present in 21% and 16%, respectively. Most cases were in the low or
low-intermediate risk group. Treatment was heterogeneous and included
chlorambucil in 59% either alone or in combination with other agents.
Complete and partial remission was achieved in 79% and 7%,
respectively, with an overall response rate of 86%. The 5- and 10-year
overall survival and cause-specific survival rates were 94%, 82% and
95%, 91%, respectively. The 5- and 10-year progression free survival
was 56% and 41%, respectively. The only feature associated with
inferior outcome was disease localisation to the lung."
}